Tivozanib Hydrochloride Rollover Protocol(Continued Access)

• Research type

  Research Study

• Full title

  A Rollover Protocol to Allow Continued Access to Tivozanib Hydrochloride (AV-951) for Subjects Enrolled in Other Tivozanib Hydrochloride Protocols

• IRAS ID

  124356

• Contact name

  Tim Eisen

• Contact email

  tgqe2@cam.ac.uk

• Sponsor organisation

  AVEO Pharmaceuticals, Inc.

• Eudract number

  2009-013407-66

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• Research summary

  This is a rollover protocol for participants who have previously taken part in other tivozanib hydrochloride studies, to allow patients to continue treatment with tivozanib hydrochloride if they are tolerating the study drug and benefiting from the treatment.

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  13/EE/0077

• Date of REC Opinion

  22 May 2013

• REC opinion

  Further Information Favourable Opinion